<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Sanofi</title>
	<atom:link href="http://www.tapanray.in/tag/sanofi/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Winning By Creating A Strong Pharma ‘Brand Identity’</title>
		<link>http://www.tapanray.in/winning-by-creating-a-strong-pharma-brand-identity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=winning-by-creating-a-strong-pharma-brand-identity</link>
		<comments>http://www.tapanray.in/winning-by-creating-a-strong-pharma-brand-identity/#comments</comments>
		<pubDate>Mon, 08 Aug 2022 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[bottom-line]]></category>
		<category><![CDATA[brand-identity]]></category>
		<category><![CDATA[brand-image]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[differentiation]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10692</guid>
		<description><![CDATA[Since the beginning of 2022, several top global pharma majors are exhibiting their renewed focus on creating a new corporate ‘brand-identity’. Its key purpose is to chart a new strategic frontier where their brands will stand out in the highly &#8230; <a href="http://www.tapanray.in/winning-by-creating-a-strong-pharma-brand-identity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/winning-by-creating-a-strong-pharma-brand-identity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Visible, The Green Shoots of Digital Transformation in Pharma</title>
		<link>http://www.tapanray.in/visible-the-green-shoots-of-digital-transformation-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=visible-the-green-shoots-of-digital-transformation-in-pharma</link>
		<comments>http://www.tapanray.in/visible-the-green-shoots-of-digital-transformation-in-pharma/#comments</comments>
		<pubDate>Mon, 22 Jul 2019 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDO]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[green]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Internet of Things]]></category>
		<category><![CDATA[IoT]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[rationalization]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulated]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[shoots]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[temporary]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[warming-up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9636</guid>
		<description><![CDATA[Currently, one gets a mixed feeling about the progress of digital transformation in the pharma industry. This is despite various reports confirming that a number of major initiatives in this field have been taken, especially by Big Pharma, globally. Moreover, &#8230; <a href="http://www.tapanray.in/visible-the-green-shoots-of-digital-transformation-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/visible-the-green-shoots-of-digital-transformation-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>While Pharma Leadership Change This Atypical Skill Counts</title>
		<link>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=while-pharma-leadership-change-this-atypical-skill-counts</link>
		<comments>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/#comments</comments>
		<pubDate>Mon, 01 Jul 2019 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digital first]]></category>
		<category><![CDATA[hardware]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[software]]></category>
		<category><![CDATA[Space]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[touchpoint]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9613</guid>
		<description><![CDATA[Effective September 01, 2019, the global pharma major Sanofi will have a new CEO, as the present CEO retires attaining his retirement age of 65 years. This appears to be a mandatory announcement from the company, as is required during the &#8230; <a href="http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Patient-Centricity: Emerging a C-Suite Role</title>
		<link>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-patient-centricity-emerging-a-c-suite-role</link>
		<comments>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/#comments</comments>
		<pubDate>Mon, 20 Aug 2018 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attributes]]></category>
		<category><![CDATA[C-suite]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[consistently]]></category>
		<category><![CDATA[CPO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[LEO]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pillars]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9110</guid>
		<description><![CDATA[Regardless of skepticism of many, the formidable power of physicians to take all treatment decisions for patients, is gradually getting moderated, globally. Although, its pace may vary from country to country. An increasing number of more informed patients are carving &#8230; <a href="http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A ‘Toxin’ Delaying Success of Biosimilar Drugs</title>
		<link>http://www.tapanray.in/a-toxin-delaying-success-of-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-toxin-delaying-success-of-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/a-toxin-delaying-success-of-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 06 Aug 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[delay]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Glaritus]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toxin]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9086</guid>
		<description><![CDATA[The above comment, although sounds a bit harsh, was made recently by none other than Scott Gottlieb - the Food and Drug Administration Commissioner of the United States. He expressed his anguish while explaining the reasons for a delayed launch of several important &#8230; <a href="http://www.tapanray.in/a-toxin-delaying-success-of-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-toxin-delaying-success-of-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Disruptive Digital Innovation To Reduce Medication Need?</title>
		<link>http://www.tapanray.in/disruptive-digital-innovation-to-reduce-medication-need/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=disruptive-digital-innovation-to-reduce-medication-need</link>
		<comments>http://www.tapanray.in/disruptive-digital-innovation-to-reduce-medication-need/#comments</comments>
		<pubDate>Mon, 01 May 2017 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alcon]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[insurgents]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[Microsoft]]></category>
		<category><![CDATA[Notes]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Playbook]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reduce]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[startups]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8202</guid>
		<description><![CDATA[Application of digital technology in various spheres of not just business, but in our individual day to life also, promises a disruptive change for the better, from the traditional way of doing things and achieving goals &#8211; freeing a lot &#8230; <a href="http://www.tapanray.in/disruptive-digital-innovation-to-reduce-medication-need/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/disruptive-digital-innovation-to-reduce-medication-need/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: First Indian Foot Print In An Uncharted Frontier</title>
		<link>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/#comments</comments>
		<pubDate>Mon, 04 Apr 2016 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[label]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[lantus XR]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[non-proprietory]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[pen]]></category>
		<category><![CDATA[pre-filled]]></category>
		<category><![CDATA[prescriber]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toujeo]]></category>
		<category><![CDATA[uncharted]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7578</guid>
		<description><![CDATA[A homegrown Indian biologic manufacturer is now about to leave behind its first foot-print, with a ‘made in India’ biosimilar drug, in one of the largest pharma market of the world. This was indeed an uncharted frontier, and a dream &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2015: Pharma Industry Achieved Some, Could Achieve Some More</title>
		<link>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=2015-pharma-industry-achieved-some-could-achieve-some-more</link>
		<comments>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/#comments</comments>
		<pubDate>Mon, 04 Jan 2016 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[achieved]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research. delivery]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[smart]]></category>
		<category><![CDATA[Social media]]></category>
		<category><![CDATA[Some]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7378</guid>
		<description><![CDATA[Wish You And All Your Near And Dear Ones Peace, Happiness, Good Health And Prosperity in The Brand New Year 2016  The year 2015 witnessed several noteworthy developments in the pharma industry, just as many other years before. That said, &#8230; <a href="http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Digital Marketing: Is Pharma Still A Laggard?</title>
		<link>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=digital-marketing-is-pharma-still-a-laggard</link>
		<comments>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/#comments</comments>
		<pubDate>Mon, 17 Aug 2015 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Cephalon]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Freebies]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[laggard]]></category>
		<category><![CDATA[Maggi]]></category>
		<category><![CDATA[Maggie]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Salford Business School]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCB]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6946</guid>
		<description><![CDATA[‘Brand Marketing’ in the pharmaceutical industry, across the world, has mostly remained tradition bound, despite its rapid embracement of modern state of the art tools and technology in most other areas of the business. Many other industries have been demonstrating &#8230; <a href="http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma &amp; Healthcare: Where The Healers Turn Looters?</title>
		<link>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-healthcare-where-the-healers-turn-looters</link>
		<comments>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/#comments</comments>
		<pubDate>Mon, 24 Nov 2014 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[300 doctors]]></category>
		<category><![CDATA[Ahmedabad]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[clothing]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[healers]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[looters]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Octreotide]]></category>
		<category><![CDATA[Octride]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sandostatin]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sheep]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tata]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Wolf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6221</guid>
		<description><![CDATA[Two news reports of the last week, though no longer shocking, made me think exactly the same way as the headline of this article epitomizes. These reports are not just two isolated instances, but an integral part of a similar &#8230; <a href="http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-healthcare-where-the-healers-turn-looters/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
